CXCR4 and diffuse large B-cell lymphoma: Differently from plerixaforand all other CXCR4 inhibitors that have a rapid reversible bond,this unique ability of BTK140 induce a stronger effect.27 BTK140 showed in vitro antiproliferativeactivity in ten cell lines of either germinal center B-cell like (GCB)DLBCL (DBr, DOHH2, SU-DHL-4, CJ, McA, OCI-LY19) and activated B-cell–like(ABC) DLBCL (OCI-LY3, WP, LR, and OCI-LY10), with IC50 valuesranging from 16.55 to 79.33 nM.